| Title |
Docetaxel-related interstitial pneumonitis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, December 2015
|
| DOI | 10.2147/tcrm.s90488 |
| Pubmed ID | |
| Authors |
Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang |
| Abstract |
Docetaxel (Taxotere(®)) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10-20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 19% |
| Student > Postgraduate | 3 | 19% |
| Student > Doctoral Student | 2 | 13% |
| Librarian | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Other | 3 | 19% |
| Unknown | 3 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Chemistry | 1 | 6% |
| Unspecified | 1 | 6% |
| Unknown | 4 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2015.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,020
of 1,323 outputs
Outputs of similar age
#275,110
of 395,418 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#37
of 43 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,418 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.